Shopping Cart
Remove All
Your shopping cart is currently empty
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $57 | In Stock | In Stock | |
| 5 mg | $139 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $359 | In Stock | In Stock | |
| 50 mg | $597 | In Stock | In Stock | |
| 100 mg | $852 | In Stock | In Stock | |
| 500 mg | $1,730 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $148 | In Stock | In Stock |
| Description | BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular. |
| Targets&IC50 | CCR5:3.6 nM, CCR2:6.2 nM |
| Synonyms | BMS 813160 |
| Molecular Weight | 484.64 |
| Formula | C25H40N8O2 |
| Cas No. | 1286279-29-5 |
| Smiles | CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C |
| Relative Density. | 1.31 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (113.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.